TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Rating of “Buy” from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have received a consensus rating of “Buy” from the eleven research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $144.80.

TMDX has been the topic of a number of recent research reports. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Stephens upped their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group cut their target price on TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. Needham & Company LLC dropped their price objective on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Finally, JPMorgan Chase & Co. cut their price objective on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th.

Insider Buying and Selling

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 61,247 shares of company stock worth $9,518,181 in the last ninety days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of TransMedics Group

Several hedge funds and other institutional investors have recently modified their holdings of the business. International Assets Investment Management LLC purchased a new stake in TransMedics Group in the 2nd quarter worth about $47,000. USA Financial Formulas acquired a new stake in shares of TransMedics Group during the third quarter worth approximately $55,000. J.Safra Asset Management Corp boosted its holdings in shares of TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC grew its position in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Fidelis Capital Partners LLC acquired a new position in TransMedics Group in the 1st quarter valued at approximately $35,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of TMDX opened at $82.40 on Monday. The company has a current ratio of 8.20, a quick ratio of 8.48 and a debt-to-equity ratio of 2.42. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of 87.66 and a beta of 2.08. TransMedics Group has a 52 week low of $38.13 and a 52 week high of $177.37. The stock has a 50 day moving average of $140.51 and a 200-day moving average of $139.98.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the previous year, the firm earned ($0.12) EPS. The firm’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, analysts forecast that TransMedics Group will post 1.08 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.